Yellowish Retinal Degeneration – A Comprehensive Medical Guide

Overview

Yellowish retinal degeneration (YRD) is an umbrella term for a group of inherited or acquired disorders in which the retina – the light‑sensitive tissue at the back of the eye – develops yellow‑colored deposits, atrophy, or pigmentary changes that progressively impair vision. The most commonly referenced condition under this name is **Stargardt‑type macular degeneration** and certain forms of **vitelliform macular dystrophy**, both of which present with a characteristic yellow‑orange lesion in the macula.

The disease usually manifests in the second to fourth decade of life, but it can appear earlier in childhood or later in adulthood, depending on the genetic subtype. While it is considered a rare disorder, population‑based studies estimate a prevalence of 1–3 per 10,000 people for the most common forms (Stargardt disease) in North America and Europe ¹. The condition affects both males and females equally, although some X‑linked variants (e.g., retinitis pigmentosa with vitelliform lesions) are more common in males.

Symptoms

Symptoms are often subtle at first and progress over months to years. Early detection is critical because visual loss can become irreversible.

• Decreased central visual acuity: Blurry or distorted vision when looking at straight‑ahead objects such as reading material or a computer screen.
• Metamorphopsia (visual distortion): Straight lines may appear wavy or bent, especially when looking at a grid or newspaper.
• Central scotoma: A dark spot in the middle of the visual field that enlarges as the disease progresses.
• Color vision changes: Difficulty distinguishing subtle shades, particularly in the red‑green spectrum.
• Glare and photophobia: Increased sensitivity to bright lights or glare from headlights.
• Difficulty adapting to low light: Although the peripheral retina is often spared, patients may notice slower adjustment when moving from bright to dim environments.
• Progressive vision loss: Over years, the central vision may decline to the point where reading and face recognition become challenging.

Causes and Risk Factors

Genetic causes

The majority of YRD cases are inherited:

• ABCA4 gene mutations: The most common cause of Stargardt disease (autosomal recessive). The gene encodes a protein involved in the transport of vitamin A derivatives across photoreceptor cell membranes. Accumulation of toxic bisretinoids leads to yellow‑white flecks and RPE (retinal pigment epithelium) atrophy.
• BEST1 gene mutations: Lead to Best vitelliform macular dystrophy (autosomal dominant). The BEST1 protein forms calcium‑activated chloride channels; dysfunctional channels cause sub‑retinal vitelliform (yellow) lesions.
• PRPH2 and PROM1 mutations: Associated with other vitelliform dystrophies and pattern dystrophies that present with yellow deposits.

Acquired causes

• Age‑related macular degeneration (AMD): Some forms of early AMD exhibit yellow drusen that can resemble YRD.
• Drug‑induced toxicity: Long‑term use of chloroquine, hydroxychloroquine, or tamoxifen may cause yellowish RPE changes.
• Systemic disease: Rarely, metabolic disorders (e.g., cystinosis) produce yellow retinal deposits.

Risk factors

• Positive family history of inherited retinal dystrophy.
• Consanguineous parentage (increases chance of recessive mutations).
• High‑intensity, prolonged exposure to bright sunlight without protection, which may accelerate photoreceptor stress in genetically susceptible individuals.
• Smoking – a known risk factor for AMD and may aggravate retinal degeneration.

Diagnosis

Because early signs can be subtle, a comprehensive eye examination performed by a retinal specialist is essential.

Clinical exam

• Visual acuity testing – baseline measurement and monitoring over time.
• Fundus examination – ophthalmoscopic view reveals yellowish flecks or vitelliform lesions in the macula.
• Amsler grid testing – patient‑performed test to detect central distortions.

Imaging & functional tests

• Optical coherence tomography (OCT): High‑resolution cross‑sectional images show sub‑retinal hyper‑reflective material (the “yellow” deposits) and RPE/photoreceptor loss.
• Fundus autofluorescence (FAF): Highlights abnormal accumulation of lipofuscin (a yellow‑fluorescent pigment) in the RPE.
• Fluorescein angiography (FA):** May demonstrate a “dark‑choroid” sign in Stargardt disease.
• Electroretinography (ERG):** Assesses overall retinal function; often normal or mildly reduced in early disease.
• Genetic testing:** Targeted panels for ABCA4, BEST1, PRPH2, and other retinal dystrophy genes confirm the diagnosis in >80% of cases ². Testing also informs prognosis and eligibility for clinical trials.